Insiders Have Been Buying Valeant Pharmaceuticals Intl Inc (VRX), Time Warner Inc (TWX), and More

We’ve also tracked an insider purchase at Valeant Pharmaceuticals Intl Inc (NYSE:VRX), a $32 billion market cap drug developer. Valeant has roughly doubled in the last year as investors have become more optimistic about the marketability of the company’s products, and in fact last quarter its revenues grew by over 30% compared to the second quarter of 2012 though profitability remains poor. Billionaire Stephen Mandel’s Lone Pine Capital had initiated a position of 4.9 million shares in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) between January and March of this year (find Mandel’s favorite stocks).

Oneok Partners LP (NYSE:OKS) saw its CEO buy more than 12,000 shares of the stock at an average price of $49.55 per share. The natural gas gathering, processing, and transportation company pays an annual yield of nearly 6% following the most recent increase in its quarterly dividend. The buildout of natural gas infrastructure is a huge opportunity as production in the onshore U.S. continues to rise, though Oneok Partners LP (NYSE:OKS) has not yet proven able to capitalize on this by converting its significant revenue growth into improvements on the bottom line.

Rounding out our list of stocks seeing recent insider purchases is $11 billion market cap retail and corporate bank KeyCorp (NYSE:KEY). The bank is valued at a small premium to some of the megabanks, with trailing and forward P/Es of 14 and 12 respectively as well as being priced slightly above the book value of its equity. We’d note that its profits have been down, in contrast to the good financial performance of many industry peers. Cliff Asness’s AQR Capital Managemnt disclosed ownership of about 11 million shares of KeyCorp (NYSE:KEY) in its most recent 13F filing (research more stocks Asness likes).

Disclosure: I own no shares of any stocks mentioned in this article.